BioSpace News Archive

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at February 1, 2023.

Mainz Biomed N.V. announced the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer being commercialized across Europe.

XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET.

Asieris Pharmaceuticals announced that the registration applications for the single-use, handheld electronic cystoscope cannula Uro-G and the electronic endoscope image processor Uro-3500 it represents have been accepted by the National Medical Products Administration.

Amydis Inc. announced initiation of enrollment of patients with cerebral amyloid angiopathy, an age-associated disease in which a protein called amyloid beta builds up on the walls of the arteries in the brain increasing the risk for stroke and dementia.

AbCheck s.r.o. announced that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm.

LEX Diagnostics announces the appointment of Scott O’Brien to the LEX Board.

Mr. Patrick Charest, B. Sc., P. Eng., CEO of Aplantex, is pleased to announce that the company has secured its first industrial facility to implement its strategic plan.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the company received a second interim response from the U.S. Food and Drug Administration to its Formal Dispute Resolution Request regarding the Complete Response Letter for vadadustat received in March 2022.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading on Monday, March 6.